ACM
CABA icon

ADAR1 Capital Management’s Cabaletta Bio CABA Stock Holding History

ADAR1 Capital Management’s Portfolio CABA Stock Details CABA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-8,900
Closed -$152K – 280
2024
Q1 		$152K Buy
+8,900
New +$191K 0.03% 131

Other funds holding CABA

Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Alkeon Capital Management
Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return
FAM
Fred Alger Management New York $22.8B AUM 64.63% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return

ADAR1 Capital Management's CABA Position: Q2 2024 in Review

ADAR1 Capital Management sold out of Cabaletta Bio (CABA) in Q2 2024, closing a stake of 8,900 shares — an estimated $152K sold.

ADAR1 Capital Management first reported a position in CABA in Q1 2024 and held it in 1 quarter. The position peaked at $152K in Q1 2024. 142 funds tracked by Wall St. Rank hold CABA as of Q2 2024.

  • ADAR1 Capital Management reported no remaining Cabaletta Bio position as of Q2 2024 after selling out during the quarter.
  • ADAR1 Capital Management sold 8,900 Cabaletta Bio shares in Q2 2024, an estimated $152K.
  • ADAR1 Capital Management first reported a position in Cabaletta Bio in Q1 2024 and held it in 1 quarter.
  • ADAR1 Capital Management's Cabaletta Bio position peaked at $152K in Q1 2024.
  • 142 funds tracked by Wall St. Rank held Cabaletta Bio as of Q2 2024.

Based on ADAR1 Capital Management's 13F filing for Q2 2024, filed 13 Aug 2024.